Spots Global Cancer Trial Database for FREDO-ODX Study: FREnch Data on Outcomes in HR+/HER2- Early Breast Cancer Patients With oncotypeDX Recurrence Score-guided Therapy
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: FREDO-ODX Study: FREnch Data on Outcomes in HR+/HER2- Early Breast Cancer Patients With oncotypeDX Recurrence Score-guided Therapy
Official Title: FREnch Data on Outcomes in HR+/HER2- Early Breast Cancer Patients With oncotypeDX Recurrence Score-guided Therapy
Study ID: NCT06185569
Conditions
Interventions
Study Description
Brief Summary: The aim of this study is to assess the clinical outcomes in real-life setting of early breast cancer RH+ HER2- patients with systemic therapy guided by Oncotype DX (ODX) Breast Recurrence Score®.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
Locations
CHU Besançon, Besançon, , France
Clinique Tivoli Ducos, Bordeaux, , France
Polyclinique Bordeaux Nord Aquitaine, Bordeaux, , France
AP-HP - Hôpital Tenon, Paris, , France
Centre Catalan d'Oncologie, Perpignan, , France
Contact Details
Name: Elsa CURTIT
Affiliation: Centre Hospitalier Universitaire de Besancon
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
